Disclosed are a new dapagliflozin crystal form and a preparation method and use thereof. In particular, disclosed are a crystal form E of 2-chloro-5-(β-D-glucopyranose-1-yl)-4′;-ethyoxyldiphenylmethane and a preparation method therefor, and a pharmaceutical composition containing a therapeutically effective amount of the crystal form and the use thereof in treating type II diabetes.